Symbiosis C.M.
Personalized Transcatheter Heart Valve Replacement
Company Overview
Snapshot
Founded in February 2021 by Shira Burg, Symbiosis C.M. operates with 11–50 employees. The company has completed 5 funding rounds. In December 2024, Symbiosis C.M. welcomed Prof. Marc Gillinov to its Advisory Board, enhancing its strategic guidance.
Business overview
Symbiosis C.M. is a medical device company focused on addressing anatomical variability in valvular heart disease. The company develops solutions to improve the fit and performance of existing medical devices, as well as standalone products for anatomies with significant inter-patient variability. Its primary product, ValSync, is a minimally invasive personalized solution for valve replacement, serving the medical devices industry within the broader healthcare and life sciences sectors.
Strategic signal
In December 2024, Symbiosis C.M. won the TCT 2024 Shark Tank Innovation Competition. This achievement signals strong validation of the company's innovative approach to personalized transcatheter heart valve replacement, highlighting its potential to disrupt the medical device market and attract further investment and partnerships in the health tech sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Symbiosis C.M.'s core product?
- Symbiosis C.M.'s first product is ValSync, a minimally invasive personalized solution designed for valve replacement, addressing anatomical variability in valvular heart disease.
- When was Symbiosis C.M. founded?
- Symbiosis C.M. was founded in February 2021.
- What recognition did Symbiosis C.M. receive in late 2024?
- In December 2024, Symbiosis C.M. won the TCT 2024 Shark Tank Innovation Competition.
- Who is the founder of Symbiosis C.M.?
- Shira Burg is the Founder & CEO of Symbiosis C.M.
- What significant addition was made to Symbiosis C.M.'s Advisory Board?
- In December 2024, Symbiosis C.M. welcomed Prof. Marc Gillinov to its Advisory Board.